PTPRC and neoplasm: Through a combination of specific antibodies for the tumor cell marker Ezh2, the pan B-cell marker B220/CD45R, and the neutrophil marker Ly6g, a significant decrease of splenic B-cells with a concomitant increase in Ly6g+ myeloid cell infiltration in tumors was revealed (Fig. 5C, D).